IL309428A - Methods of using aldosterone synthase inhibitors - Google Patents

Methods of using aldosterone synthase inhibitors

Info

Publication number
IL309428A
IL309428A IL309428A IL30942823A IL309428A IL 309428 A IL309428 A IL 309428A IL 309428 A IL309428 A IL 309428A IL 30942823 A IL30942823 A IL 30942823A IL 309428 A IL309428 A IL 309428A
Authority
IL
Israel
Prior art keywords
methods
synthesis inhibitors
aldosterone synthesis
aldosterone
inhibitors
Prior art date
Application number
IL309428A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cincor Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincor Pharma Inc filed Critical Cincor Pharma Inc
Publication of IL309428A publication Critical patent/IL309428A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL309428A 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors IL309428A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US202163290364P 2021-12-16 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
IL309428A true IL309428A (en) 2024-02-01

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309428A IL309428A (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Country Status (10)

Country Link
US (1) US20240277698A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358959A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523559A (cg-RX-API-DMAC7.html)
KR (1) KR20240035483A (cg-RX-API-DMAC7.html)
AU (2) AU2022299103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023027025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223211A1 (cg-RX-API-DMAC7.html)
IL (1) IL309428A (cg-RX-API-DMAC7.html)
MX (1) MX2023015121A (cg-RX-API-DMAC7.html)
WO (1) WO2022272300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026521801A (ja) * 2023-06-29 2026-07-01 アストラゼネカ アイルランド リミテッド バクスドロスタットの結晶形、並びにその製造方法及びその使用
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
IL329013A (en) * 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension
WO2026120166A1 (en) 2024-12-06 2026-06-11 AstraZeneca Ireland Limited Tablet formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2832996C (en) * 2011-04-26 2019-05-07 Merck Sharp & Dohme Corp. Tricyclic triazole compounds and their use as aldosterone synthase inhibitors
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
CA3223211A1 (en) 2022-12-29
WO2022272300A1 (en) 2022-12-29
MX2023015121A (es) 2024-04-16
KR20240035483A (ko) 2024-03-15
US20240277698A1 (en) 2024-08-22
JP2024523559A (ja) 2024-06-28
AU2026201954A1 (en) 2026-04-02
AU2022299103A1 (en) 2024-01-25
EP4358959A4 (en) 2025-05-14
BR112023027025A2 (pt) 2024-03-12
AU2022299103B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
IL292754A (en) Method of synthesis
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL286352A (en) Novel small molecule inhibitors of tead transcription factors
IL287940A (en) Fgfr inhibitors and methods of use thereof
AR120184A1 (es) Aminas bicíclicas como inhibidoras de la cdk2
EP4110333A4 (en) Sos1 inhibitors
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
PL3752251T4 (pl) Inhibitory arginazy i sposoby ich stosowania
EP4358989A4 (en) BICYCLIC PEPTIDYL PAN-RAS INHIBITORS
EP4358963A4 (en) SOS1 INHIBITORS
EP4225310A4 (en) HETEROARYL AMIDE INHIBITORS OF CD38
IL314221A (en) Synthesis of a kif18a inhibitor
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
IL292860A (en) Allosteric egfr inhibitors and methods of use thereof
IL299700A (en) Kcnt1 inhibitors and methods of use
EP4358959A4 (en) Methods of using aldosterone synthase inhibition
IL309571A (en) Cdk2 inhibitors and methods of using the same
EP4247372A4 (en) PLASMA KALLICREIN INHIBITORS
PT4221709T (pt) Inibidores de imidazopiperazina das proteínas ativadoras da transcrição
DK4192813T3 (da) Inhibitorer af transglutaminaser
IL313475A (en) Use of isoxazolinecarboxamide for sprout inhibition
EP4210694A4 (en) PLASMA KALLICREIN INHIBITORS
EP4178620A4 (en) PLASMA KALLICREIN INHIBITORS